Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: a positive sector close, 2 out of 8 for October so far

October 10, 2019 6:43pm

Low volume and slim percentage moves have populated the up and downsides

So, why motivate investors to enter a “kill zone” as earnings’ season is about to begin and depreciation sets-in, the truth is hard that does usually play out?

It’s all about trading into volume and playing out to strength when it returns

The sector is what it is, until it isn’t and even then it doesn’t seem to be …

I think Aristotle may have been the first to crystallize the fallacies (in writing at least) of many situations we are trying to deal with. Ad Verecundiam (Appeal to Authority) is certainly one fallacy, Ad Metum (Appeal to Fear) is the answer to the argument!

The Dow closed up +150.66 points (+0.57%), the S&P closed up +18.73 points (+0.64%) and the NASDAQ closed up +47.04 points (+0.60%)

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Thursday the IBB closed up +1.25% while the XBI closed up +1.33%
Wednesday the IBB closed up +0.14% while the XBI closed down -0.33%
Tuesday the IBB closed down -1.80% while the XBI closed down -1.52%
Monday the IBB closed up +0.18% while the XBI closed down -0.08%

Henry’omics:

A breakout for the oversold with low volume – an indicator of trouble ahead!

Who knows what will come out of the negotiations with china, the “phantom” knows, remember him?

I wouldn’t be holding my breath for the laundry list of U.S. “issues” with China – we need better relations and both countries need to understand the needs of their codependence and cooperation for growth to the future!

I am MORE concerned about the reality of reporting by media sources re the status of talks re the “fluidity” of the negotiations.

More facts are needed; not opinions of "questionable" news “sources”!

The advance/decline line scenario of 45 covered companies:

Thursday the close was positive with an A/D line of 23/17, 2 flats, 1 reversed merged (HSGX) and 2 acquired;
Wednesday the close was negative with an A/D line of 11/27, 4 flats, 1 reversed merged (HSGX) and 2 acquired;
Tuesday the close was negative with an A/D line of 4/37, 1 flat, 1 reversed merged (HSGX) and 2 acquired;
Monday the close was negative with an A/D line of 17/25, 1 flat and 2 acquired;

Decliners:

Spark Therapeutics (ONCE -$1.76);
Sage Therapeutics (SAGE -$1.33 after Wednesday’s -$2.21);
Global Blood Therapeutics (GBT -$1.18 after Wednesday’s +$0.69, Tuesday’s +$0.76 and Monday’s -$2.36);
bluebird bio (BLUE -$0.82 after Wednesday’s +$1.42);
Voyager therapeutics (VYGR -$0.51);

Incliners:

ReNeuron (RENE.L +$3.50 after Wednesday’s -$2.50, Tuesday’s-$10.00 and Monday’s -$2.50;
Ions Pharmaceuticals (IONS +$2.36 after Wednesday’s +$1.03, Tuesday’s -$1.40 and Monday’s +$1.47);
BioMarin Pharmaceuticals (BMRN +1.45);
Regenxbio (RGNX +$1.16 after Wednesday’s +$0.87);
Audentes Therapeutics (BOLD +$1.02);

The percentage (%) indicators:

Thursday’s range of the 23 upside was +0.22% (CRSP) to +5.957% (BSTG) while the 17 downside ranged from -0.02% (CLLS) to -3.33% (VYGR);
Wednesday’s range of the 11 upside was +0.31% (ADRO) to +2.36% (RGNX) while the 27 downside ranged from -0.64% (SLDB) to -11.81% (CLBS);
Tuesday’s range of the 4 upside was +0.07% (FATE) to +3.07% (BSTG) while the 37 downside ranged from -0.01% (BLUE) to -9.62% (NTLA);
Monday’s range of the 17 upside was +0.47% (ONCE) to +5.36% (ONVO) while the 25 downside ranged from -0.05% (ALNY) to -7.08% (BTX);

Upside volume stats:

Thursday: 6 out of the 23 upside had higher than the 3 month average volume;
Wednesday: 3 out of the 11 upside had higher than the 3 month average volume;
Tuesday: 2 out of the 4 upside had higher than the 3 month average volume;
Monday: 3 out of the 17 upside had higher than the 3 month average volume;

Downside volume stats:

Thursday: 5 out of the 17 downside had higher than the 3 month average volume;
Wednesday: 10 out of the 27 downside had higher than the 3 month average volume;
Tuesday: 10 out of the 37 downside had higher than the 3 month average volume;
Monday: 8 out of the 25 downside had higher than the 3 month average volume;

2 flat – VSTM and MDXG with 1, reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche is still being delayed (October?)

October’s sessions:

Thursday closed POSITIVE with 17 decliners, 23 advancers, 2 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 27 decliners, 12 advancers, 3 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 38 decliners, 4 advancers, 1 flat and 1 reverse merged (HSGX), 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 25 decliners, 17 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 17 decliners, 24 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEUTRAL with 21 decliners, 21 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 36 decliners, 5 advancers, 2 flat and 2 acquired (AST & OSIR);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.